Nateglinide

Clinical data
Trade names	Starlix
AHFS/Drugs.com	Monograph
MedlinePlus	a699057
License data	EU EMA: by INN US FDA: Nateglinide
Routes of administration	Oral
ATC code	A10BX03 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Protein binding	98%
Elimination half-life	1.5 hours
Identifiers
IUPAC name (2R)-2-({[trans-4-(1-methylethyl)cyclohexyl]carbonyl}amino)-3-phenylpropanoic acid
CAS Number	105816-04-4 Y
PubChem CID	60026
IUPHAR/BPS	6833
DrugBank	DB00731 Y
ChemSpider	10482084 Y
UNII	41X3PWK4O2
KEGG	D01111 N
ChEBI	CHEBI:31897 N
ChEMBL	ChEMBL286559 N
CompTox Dashboard (EPA)	DTXSID9040687
ECHA InfoCard	100.170.086
Chemical and physical data
Formula	C19H27NO3
Molar mass	317.429 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(N[C@H](Cc1ccccc1)C(O)=O)[C@H]2CC[C@@H](CC2)C(C)C
InChI InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1 Y Key:OELFLUMRDSZNSF-BRWVUGGUSA-N Y
NY (what is this?)  (verify)

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.

Pharmacology[edit]

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

Contraindications[edit]

Nateglinide is contraindicated in patients who:

• have known hypersensitivity to the compound or any ingredient in the formulation.
• are affected with type 1 (namely insulin-dependent) diabetes mellitus.
• are in diabetic ketoacidosis.

Comparisons with other drugs for type 2 diabetes[edit]

A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial".^[1] They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values after 16 weeks of therapy."

Dosage[edit]

Nateglinide is delivered in 60 mg & 120 mg tablet form.

See also[edit]

• Repaglinide

References[edit]

External links[edit]

• Starlix - website of the manufacturer.
• How Nateglinide Works - website of the manufacturer.